In short
The episode is primarily about two separate news/ideas segments. First, Bloomberg legal reporter Eric Larson discusses Andrew Left, the famed short seller behind Citron Research, who was found guilty of manipulating stocks using disingenuous social media posts. Larson says the Justice Department argued Left traded opposite to what he publicly claimed, timing trades with tweets/research reports between 2018 and 2023. Key claims include that Left made about $20 million in profits and that more than a dozen companies were central, including Twitter, Facebook, and NVIDIA. Notable examples are the alleged pattern of arranging trades via private communications (Telegram, emails, texts) to coincide with public bearish or bullish messaging. Larson also notes experts warn the verdict could chill short selling due to unclear legal lines and potential appeal.
Later, the show pivots to AI skepticism with Ed Zitron (Easy Primary Research; Better Offline podcast; Where’s Your Ed At newsletter), who argues AI lacks measurable ROI and that many AI firms are unprofitable.
Written by AI. May contain mistakes. Listen to the episode to check what was said.
Chapters
Tap a time to open that second in VOIntroduction to Andrew Left's Case
0:45 to 1:04
Overview of the case against Andrew Left and its implications.
“They bring people together, create opportunities, and drive growth.”
Introduction to Andrew Left's Case
1:17 to 1:54
Overview of the case against Andrew Left and its implications.
Understanding Andrew Left and Citron Research
1:54 to 3:56
Discussion on Andrew Left's background and his manipulation tactics.
“This is one of the most read stories on the Bloomberg Terminal in the past day.”
The Implications of the Verdict
3:56 to 6:30
Exploration of the potential chilling effects on the short selling industry.
“But the point that the government was making was that he was trading opposite, essentially, of what he was saying on Twitter and in his reports about companies.”
Appeal Possibilities and Future Developments
6:30 to 9:01
Discussion on possible legal appeals and ongoing challenges for Andrew Left.
“They already started to beef up their disclaimers and things like that.”
Introduction to Trump's Audit Immunity Case
9:01 to 9:53
Transition to discussing Donald Trump's audit immunity agreement.
“More from Bloomberg Businessweek Daily coming up after this.”
Introduction to Trump's Audit Immunity Case
9:59 to 10:14
Transition to discussing Donald Trump's audit immunity agreement.
“complete disclosures at public.com slash disclosures.”
Skepticism Around AI Investments
10:14 to 14:00
Discussion on AI investment skepticism and the economic realities.
“We believe in starting with your financial goals, not a formula.”
Winners and Losers in AI Investment
14:00 to 15:00
Explore who benefits in the current AI landscape and the challenges companies face.
“Do you not see some winners and losers in this or some winners in this?”
Amazon's Journey: A Case Study
15:00 to 16:40
Learn how Amazon's path to profitability can inform current AI companies' strategies.
“And now it's a, you know, then AWS came along.”
Show all 28 chapters
The Rock-Com Bubble Theory
16:40 to 18:20
Discover the theory linking hyperscalers' investments in AI to a potential bubble.
“So I have this theory called the rock-com bubble, which is the hyperscalers are out of hyper-growth ideas We haven't had a new iPhone.”
Market Irrationality and Company Scrutiny
18:20 to 20:00
Discuss the perceived lack of scrutiny on companies like OpenAI and Anthropic.
“They're spending about as much in CapEx, ironically, as Amazon was spending on AWS way back when.”
The Case Against IPOs for AI Companies
20:00 to 21:40
Examine the reasons why OpenAI and Anthropic should not go public.
“I think the majority of gains based on AI success are going away.”
The ROI Conversation in AI
21:40 to 23:20
Understand the misconceptions around AI costs and profitability.
“They do not have a path to profitability.”
Economic News and Job Market Insights
23:20 to 24:00
Get insights into the current job market and economic conditions from the labor market.
“used by its staff to manage costs after blowing through its AI budget earlier this year.”
Middle Market Dynamics with Wendy Stewart
24:00 to 28:00
Learn how middle market businesses are navigating economic challenges and opportunities.
“It's a big week, actually, for the labor market, but we did get a read today.”
Geopolitical Changes Affecting Business Relationships
28:00 to 29:26
Learn how geopolitical uncertainties influence business strategies and client relationships between U.S. and Canada.
“To me, it would say no, but tell me what you're hearing.”
Sector Strengths and Challenges
29:26 to 30:46
Discover which sectors are currently thriving and the specific challenges they face.
“And so, regardless of where they're doing business, we're able to support them.”
AI's Impact on Business Operations
30:46 to 32:40
Understand how businesses are leveraging AI to enhance customer experience and efficiency.
“And the fourth thing is to drive efficiency.”
AI's Impact on Business Operations
32:43 to 33:08
Understand how businesses are leveraging AI to enhance customer experience and efficiency.
Exploring Longevity Science
34:32 to 35:34
Discover the latest advancements in longevity research and their implications for health.
“Wasabi Hot Cloud Storage, proud partner of iHeart Podcast Network.”
Therapeutic Approaches to Aging
35:34 to 38:12
Learn about innovative therapies targeting the biological triggers of aging.
“Karina Kern is founder and CEO of Longevity.”
Navigating Regulatory Challenges in Medicine
38:12 to 41:18
Understand the complexities of getting new therapies approved in the medical field.
“So I think very much as Karina said, we are working with regulators on this.”
Paradigm Shift in Medical Development
41:18 to 42:00
Explore the need for a new approach in drug discovery and the challenges of aging.
Paradigm Shift in Medicine for Aging
42:00 to 43:54
Explore the need for a new approach in drug discovery that addresses aging and multi-morbidity.
“can cost thousands of dollars that only really wealthy people can afford and at the end of the day it's like a total waste of money Dr.”
Funding and Research Strategies
43:54 to 45:08
Learn about the funding strategies and partnerships in biotech research.
“And for me, necrosis is such a powerful therapeutic target because those mechanisms have been characterized for the last decades.”
Navigating Biotech Company Challenges
45:08 to 46:30
Understand the challenges biotech companies face and the importance of drug development timelines.
“And again, remind us when that clinical trial gets underway.”
Navigating Biotech Company Challenges
47:09 to 48:09
Understand the challenges biotech companies face and the importance of drug development timelines.
“With Genius by Global Payments, online orders actually sink straight into your kitchen.”
Transcript
Automatic transcript. May contain errors.0:00This coffee shop? Running smooth thanks to Genius. From Global Payments, instant transactions, effortless inventory, and synchronized operations. Big League reliability for any business. That's Genius. Never bet against American grit or American energy. Through innovation, Venture Global is not only building some of the largest energy facilities in the world right here in the United States, but delivering American energy at a fraction of the cost and a fraction of the time. So while others are busy talking, we're busy building. That's Venture Global. That's Unstoppable Energy.
0:44Small businesses are the pulse of every community. They bring people together, create opportunities, and drive growth. Chase for Business helps business owners like you with personalized guidance and convenient digital tools all in one place. With that guidance and your determination, you can take your business farther and help build a brighter future for your community. Learn more at chase.com slash business. Chase for business. Make more of what's yours. The Chase Mobile app is available for select mobile devices. Message and data rates may apply. JPMorgan Chase Bank, N.A. Member FDIC. Copyright 2026.
1:20JPMorgan Chase and Company. Bloomberg Audio Studios. Podcasts, radio, news.
1:54This is one of the most read stories on the Bloomberg Terminal in the past day. It crossed late yesterday. We got more details on it overnight. It's about the famed short seller Andrew Left. He faces the possibility of decades behind bars. He was found guilty of using disingenuous social media posts to manipulate stocks. In a landmark case, it threatens to chill a broader trading strategy that's just loathed by corporate executives. We've got Eric Larson with us. He's U.S. legal reporter for Bloomberg News. He joins us from Los Angeles. Eric, just remind us who Andrew Left is, what Citron Research made a name doing.
2:27Sure. As you said, he grew a big following on Twitter, actually, where he got so many followers tracking everything he was saying about companies that he was researching through his Citron research. He made some good calls back in the day on a few companies that gained him extra followers. And really, this group that was following him is who he tried to manipulate here, according to the Justice Department. So you mentioned this trading strategies that's loathed by companies. It has to do with building a short position on a company and then trashing it in a research report or tweets in Mr. Left's case.
3:03And so the government said that Mr. Left went a little beyond just doing that. So it's a really, like you said, it's a landmark case. And the short selling industry is really wondering what it means. You know, I always find it interesting, Eric, because I think about people can like a stock, talk it up, put out research, right? But when we get into short selling, everybody gets a little bit hinky about that particular side of the trade. Is it a legal term? Yeah, it is. It's hinky go on the Bloomberg Journal. All right, check with Eric. Go ahead. I was going to say that word didn't come up at trial.
3:39So what is it that he did, though? Like if he, you know, talked it down and then was trading accordingly, but was he not trading? Did the trading not match up with what he was saying? I guess essentially. Well, that's exactly what it gets at. It wasn't just his shorts that were on trial here, some of his long bets as well. But the point that the government was making was that he was trading opposite, essentially, of what he was saying on Twitter and in his reports about companies. You know, more than a dozen companies were central to this, including Twitter itself, Facebook, NVIDIA even. And these were companies that he talked about a lot in this time span between 2018 and 2023 is what was central to this case.
4:23And he made$20 million in profits betting around some of these specific reports and tweets even that he put out. And the government looked at all of his private communications, his telegram communications, his emails, his texts to show a pattern of arranging specific trades right to time with his tweets and his reports that were opposite of essentially what he was saying. So that's where the manipulation came in. It goes a little farther than just trading around your own report that you put out as a short seller. But it was a novel case. The prosecution had to explain it to this jury. And the defense really tried to pick it apart and say that Mr.
5:04Left had done nothing wrong. And ultimately, of course, he was found guilty. One of the elements of this that I want to talk to you about, Eric, and I brought it up on our editorial call this morning, is what some of the experts quoted in your piece say about the effects this could have on short sellers. And Carol and I have talked about this in the past. This came up a few years ago because Elon Musk was really, he's battled short sellers for years. And there are people out there who say short sellers serve a really important part of efficient markets in terms of bringing information to light.
5:36And I'm curious what the folks who are at the business schools or the accounting professors who study short selling and its effect on markets, think about a case such as this. Yeah, I've spoken to several since this verdict and actually even before the trial who said that this would just have a chilling effect if he were convicted. And the reason being that there's a really lightly regulated industry, right? I mean, there's not any rules specifically around a short seller trading around their own research reports and that sort of thing. And that's an argument that Mr. Left made at trial, and the government didn't really challenge him on that.
6:12But the question now is whether or not this verdict is resulting essentially in new regulations via jury verdict that aren't really clear where's the line. And all of that is just going to have a further chilling effect on the industry, which started after Mr. Left was indicted a couple of years ago. They already started to beef up their disclaimers and things like that. But without a real clear line about where, you know, why the jury specifically found the way it did, you know, they're not regulators. So it's really up in the air right now, like what this means exactly for the industry. He could still fight this?
6:49Absolutely. I spoke to him outside of the courtroom minutes after he was convicted. He hinted at an appeal saying that this wasn't the end of the road. You know, his lawyer also asked for a mistrial based on something funny that happened in court or unusual, I should say. So there's going to be a couple of different ways that they're going to challenge this. And of course, anything is possible on appeal. OK, I want to talk audit immunity. This is a story that I know has come up on our radar today. And I'm curious, U.S. officials are continuing with an agreement that bars the government from probing past tax filings from President Donald Trump and his businesses.
7:30It's another story that you worked on, a little bit of a hard pivot from talking about this insider or this rather this short selling prosecution. What can you tell us about the relationship between that one point eight billion dollar fund and audit immunity that President Trump could receive? Well, I think everyone can agree it's it's all been highly unusual. President Trump's ten billion dollar lawsuit against the IRS was unusual in itself. And then this$1.8 billion fund was also pretty unheard of, especially since it wasn't approved by a court or judge or anything like that. So the fact that this audit angle is still surviving after the settlement or the fund was dropped is pretty interesting.
8:19Of course, it's a big scoop by my legal colleague, Chris Strom. And I think that it just shows the extent to which this lawsuit had become a vehicle for Trump to get different things that he wanted from the government that he leads. So it is it is very unusual. I think that we can see we will continue to see legal challenges around this. A lot of different groups have a filing in court saying Trump's guaranteed to drop this fund isn't enough. They want something formal in court about it. And I think we'll see something similar with the audit angle. All right. Well, we'll see ultimately right where all this lands.
8:59Eric, thanks so much. As Tim mentioned earlier, especially that story about Andrew left that Eric has on the Bloomberg. It is among our most read. Eric Larson, U.S. legal reporter here at Bloomberg News. Stay with us. More from Bloomberg Businessweek Daily coming up after this.
9:17support for the show comes from public lately it feels like there are two types of investing platforms some are traditional brokerages that haven't changed much in decades and others feel less like investing and more like a game public is positioned differently it's an investing platform for people who are serious about building their wealth on public you can build a portfolio of stocks options bonds crypto without all the bugs or the confetti retirement accounts yep High-yield cash? Yes, again. They even have direct indexing. Public has modern design, powerful tools, and customer support that actually helps.
9:53Go to public.com slash market and earn an uncapped 1 % bonus when you transfer your portfolio. That's public.com slash market.
10:13complete disclosures at public.com slash disclosures. We believe in starting with your financial goals, not a formula. At Oppenheimer, we put the full strength of our longstanding expertise to work, understanding your life and your ambitions, and designing the precise strategies that build and protect your wealth with confidence across this generation and the next. Put the power of Oppenheimer thinking to work for you. Wealth management, capital markets, investment banking.
11:12months only. Then full price plan options available. Taxes and fees extra. See full terms at mintmobile.com. You're listening to the Bloomberg Business Week Daily Podcast. Catch us live weekday afternoons from 2 to 5 p.m. Eastern. Listen on Apple CarPlay and Android Auto with the Bloomberg Business App or watch us live on YouTube. Carol, I think it's fair to say we talk to a lot of folks who are bullish on AI. Yes, a lot of people, but a lot of people have skin in the game, too. Yeah, they do. You don't have to look far to see how investors in the public and private markets are viewing this stuff, OpenAI and Anthropic, fetching close to a trillion dollar valuations in the private markets before they even IPO.
11:49In terms of bullish guys, Ed Zitron is not one of those guys. He thinks, quote, AI doesn't have an ROI, which is actually the title of his sub stack today. Ed is the CEO of Easy Primary Research, also the host of the Better Offline podcast. He also writes the Where's Your Ed At newsletter. Journalists know him, too, as a tech PR guy, but increasingly he's become known as a prominent skeptic of artificial intelligence. Ed joins us here in the Bloomberg Interactive Brokers Studio. Welcome. It's good to have you on the program. Very happy to be here. Usually you're behind the scenes, so this is pretty cool.
12:22Oh, I love it, though. I live for the microphone. Well, what are we getting? I don't want to say we. What are the bulls out there getting wrong about AI? Because you've made no secret that you don't see any there there. Yeah. So I think people are conflating a semiconductor rally with an underlying successful business, which doesn't really exist. Anthropik's current revenue growth, which is deeply questionable in the fact that they leaked profitability, manipulated by Elon Musk, of course, their growth is coming because people cannot measure how much an AI task actually costs. And a couple months ago, Anthropik started charging their enterprise customers the actual token rates.
12:58What this has led to is suddenly businesses are going, oh, how much money are we spending? Uber's see, I think it was Uber's COO, Andrew McDonald said that they are having trouble justifying by the AI spend based on the actual return that one could actually measure it. So you've got a thing where you can't measure the costs and you can't measure the return on investment. What do you call that? You call it a thing without an ROI. Isn't it though safe to say, Ed, like I think about this, I agree that there is going to be, when there's any new technology, there's a lot of money thrown at something, right?
13:32A hot new idea, whatever it is. And that ultimately, like we've talked with some experts in the AI world, they're saying all of these large language models, not everything's going to exist because right now it doesn't cost you anything to use it. But at some point there will be a cost and people will start to select what they want to play with. And so is it a case of right now, I mean, at some point there will be some winners, some losers, and we'll see some things filter their way out and that there will be some return on investment for some of the larger players when it comes to AI? Do you not see some winners and losers in this or some winners in this?
14:09I think the winner is Jensen Huang and the winner is the construction firms who have got prepaid for all the data center construction. Maybe Sam Altman and Dario Amadei have become billionaires through this. But when it comes to the actual businesses, you can't find anyone who can measure the ROI because you can't do it. So when it comes down to the model companies themselves, they're horrifyingly, horrifyingly unprofitable. I think OpenAI lost like 20-something billion dollars last year. Anthropik's probably not far behind this. And we don't have access to their books. Of course, of course. But once they file for an IPO...
14:40And that's the thing. When we see these S1s, I think it's going to be kind of a massacre. Because I think that people have this view that these companies are becoming more profitable or even have a path to profitability. And they don't have one. But, you know, somebody could say, and Carol, we talk about this all the time, Amazon for years didn't really have profits. Well, that's the thing, though. Now it's a behemoth. And now it's a, you know, then AWS came along. And now it's this juggernaut that, you know, has made a lot of people very wealthy. But the thing with Amazon is between 2003 and 2017, Amazon Web Services, actually all Amazon CapEx, was around$57 billion normalized for inflation.
15:19Between that whole time. In that entire time. and they were cash flow positive in nine. The classic thing with the dot-com reconciliation thing as well, things went poorly, but after that, there was useful infrastructure. No such story exists here. GPUs, AI GPUs specifically, have very few other use cases. And on top of that, if you're talking about incomplete data centers, it's going to cost just as much money to finish them today as it will in 10 years. And similarly, a B200, GB200 rack, MVL72 rack, for example, will cost just as much, if not more, in electricity 10 years from now. There is no pick up and fix this story.
15:55Perhaps there'll be some on-device large language model use, but we are talking in an industry that has absorbed over a trillion dollars in the last three years. The media attention from everyone and these continual stories about the magic of AI. But when you say, hey, is it making any money? They go, oh, no. Oh, we couldn't possibly. We don't do that yet. But don't worry. Uber lost a lot of money. Uber burned about$32 billion, which is less than half of what Anthropic has raised in the last six months. So I think it's safe to say there's a lot of smart investors are in this. Smart companies are in it, right?
16:30Who are, I mean, pick your big hyperscaler. They obviously want to be around for a long time. So I'm just, like, how do you explain their bets on all of this? So I have this theory called the rock-com bubble, which is the hyperscalers are out of hyper-growth ideas We haven't had a new iPhone. We haven't had a new cloud computing We haven't really had a new platform that would turn into the next hundred bit the next Google search or Amazon web services So they thought that large language models were going to be the panacea that they were going to be creators of API growth that they were going to be the new infrastructure play load up the GPUs sell access to everyone the problem is no one checked to make sure any of this was profitable.
17:13And we still don't know if GPU compute is actually margin positive, which is crazy considering the amount of money going into it. And when we look at the companies that actually are selling it, Corwee, for example, they burn billions of dollars, 20-something billion dollars worth of CapEx this year, about the same amount in debt. And their customers are NVIDIA, OpenAI through Google, OpenAI through Microsoft, and Meta, who does not have an AI strategy. It's very strange to let that Twilight Zone episode with the scary child. We're all trying to pretend that Meta actually has a plan here. They don't have one.
17:50So is Apple kind of smart? Because we've talked with our Mark Gurman about this, how they've kind of been relying on Google, right, and Gemini, and not necessarily doing that big spend. And they're not doing any CapEx on. No, exactly. Well, I think what happened with Apple is they released Apple Intelligence, which may be the largest-scale anti-tech radicalization in history. My non-tech friends, I've heard nothing about AI from them. The moment Apple Intelligence comes out, they're like, this is the worst thing I've ever used. And I think that made Apple go, maybe not. Maybe we should take a step back.
18:21But their CapEx is minimal. They're spending about as much in CapEx, ironically, as Amazon was spending on AWS way back when. So I think Apple is cautiously holding back and kind of absorbing the headline after headline, the ridiculous headline of Apple's behind in AI, behind in a losing proposition, more like. We're speaking with Ed Zitron. He's the founder and CEO of Easy Primary Research. He's got the Better Offline podcast. He writes the Where's Your Ed at newsletter. Just so everybody's aware, do you have skin in the game? Are you shorting any of these companies? Do you have a financial interest in what you're talking about?
18:57I invest in words. I love doing the newsletter. I do I think I'm spreader a Spreading a great deal of financial literacy and of how to pull apart the narratives these companies But no I don't because the market is irrational and the market is inherently invested in something that I think is destructive Especially the SpaceX IPO and opening Ionanthropic should not be allowed to go public They are dangerous lossy companies. They're going to be added to indices that will sink 401ks You know, it's interesting that you say this because I got a text from on a group chat today about from a from a friend of mine who's like not happy about the idea that he's as an index fund investor, he's going to be forced to have to buy SpaceX, for example, which is the sort of the subject of yesterday's big take.
19:40Everybody should check it out on the Bloomberg Terminal. There's a lot we want to get to with you. We have a couple more minutes. You've got to come back some more with us before you go. What happens if markets you said markets are irrational right now? Now, if markets become efficient, and I think a lot of people think markets are efficient, if markets view this the way that you're viewing this, what are the repercussions of that bubble bursting? I think the majority of gains based on AI success are going away. I think the neoclouds like Iron, CoreWeave, CipherMining, and TerraWolf as well, all of them, perhaps not going to zero, but they're going to be shells of the corporations they used to be.
20:19I actually don't know how call we've survived this. I think NVIDIA is looking for the most aggressive haircut you've ever seen. For example, because they currently are not the way I've, based on research I've done, it looks like it's taking about 6 to 12 months to install a single quarter's worth of GPUs from NVIDIA. They've yet to put out any kind of guidance about this. They clearly know. But if you go and look at Microsoft, for example, none of the data centers that they have announced have broken ground since 2023 have actually been finished. The Fairwater data centers, they've said that that was fully complete.
20:56It's not even half complete. It's one of the strangest things I've seen in history. And I think what it is, is that these companies know that they can get away with it. They know that the SEC scrutiny isn't there. And they also know that the froth is big enough that everyone kind of loses together. It all comes out in the wash when it's proven that there is not a there there. Do you get calls from these companies? No, I don't hear back from Microsoft or OpenAI or any of them. But you reach out? I do. I ask for comment and they just, I guess my email gets lost. Sam Orman, Dario Amadei, there's PR people have mentioned coming on my show, but then they go quiet.
21:30Probably because I'm quite critical of them. They know I'd ask the questions they don't want to answer. Why do you think, I want to poke at something that you mentioned earlier. Why do you think OpenAI and Anthropics shouldn't be allowed to go public? Because they are lossy companies. They do not have a path to profitability. Anthropic, they leaked, or however, that they were profitable. They were profitable in two months when Elon Musk gave them a discount on their compute through SpaceX. Clearly planned leaks. Clearly planned financial engineering. No normal profitable company does things like this.
22:03OpenAI and Anthropic are both horribly unprofitable, and they are not getting better. The information reported a few weeks ago, OpenAI had a negative 122 % non-gap operating margin in the last quarter. But again, just because a company doesn't make money doesn't mean it shouldn't go public. Just because a company is not profitable doesn't mean it shouldn't go public. Let me reframe this then. I don't think these companies will survive. And I think that investors are doing exit liquidity for venture capital. And I think that these are dangerous, unstable companies that face basically no real scrutiny for most of the years of their investment.
22:42You have journalists and analysts who are actively cheering them on. This is a dangerous precedent, and it's a dangerous thing for retail investors who are being conned by this. And I mean the whole ROI conversation. That is a result of most people experiencing AI via subscriptions that are subsidized, meaning you can burn anywhere from$3 to$13.50 for every dollar of your subscription. So people don't know how much this stuff actually costs, and they are investing and believing in it and creating workflows around it based on services they likely cannot afford long-term. Just got 20 seconds here.
23:16So we have a story. Uber has set usage caps on some AI-powered tools used by its staff to manage costs after blowing through its AI budget earlier this year. We're going to increasingly see these stories in your view? Yes, we will. And we've already heard a similar story coming out of Walmart. I think Bloomberg reported yesterday. Ed, thank you so much. Great stuff. Come back soon. I agree, Tim. Great conversation. My pleasure. Thank you. Ed Zitron, CEO of Easy Primary Research, the host of the Better Offline podcast. He writes the Where's Your Ed At newsletter, joining us here in the Bloomberg Interactive Brokers Studio.
23:48This is the Bloomberg Business Week Daily Podcast. Listen live each weekday starting at 2 p.m. Eastern on Apple CarPlay and Android Auto with the Bloomberg Business app. You can also listen live on Amazon Alexa from our flagship New York station. Just say Alexa. Play Bloomberg 1130. So some of the economic news. It's a big week, actually, for the labor market, but we did get a read today. U.S. job openings jumping in April to the highest level in almost two years, and layoffs fell, adding to signs that the labor market, Tim, remained resilient. Even so, though, there's maybe still some concerns.
Read the full transcript
24:21Yeah, surveys suggest businesses and workers remain anxious about the labor market and economic conditions. The share of consumers who said jobs were plentiful fell and made to the lowest going back to 2021. That's according to the conference board. It all leads to that monthly jobs report that you mentioned on Friday, Carol. I have to tell you anecdotally, again, anecdotally, people say this market is so tough to find new jobs in. Low hire, low fire environment. And we keep putting story after story on the Bloomberg about folks that are graduating kids and how difficult it is to find jobs, even to find internships.
24:54Let's say you're a junior and that junior internship in college is so important. Did you see that on the terminal? Were you here then last week? That was a big story last week. The entry-level jobs, not there. Yeah, exactly. And so it's very interesting, especially when you hear people say the economy is doing okay. And we want to ask our next guest that. We welcome Wendy Stewart. She's president of Global Commercial Banking at Bank of America. They remind us that they serve one in five U.S. middle market clients with annual revenues of$50 million to$2 billion, as well as more than one-third of U.S.
25:24Fortune 1000 companies. She sees a lot. Wendy joins us here in studio. Welcome. So nice to have you here. Thank you. And I appreciate the opportunity to be with you this afternoon. Well, tell us about, you guys have a great vantage point. I love middle market. That is so much a part of our economy. Tell us what you're seeing and what you're, in terms of lending activity, business activity, concerns, how would you describe how middle markets kind of, or middle market businesses see the world right now? Well, it's a terrific business. And so when we talk about middle market companies, we cover U.S.
25:55and Canadian-based companies. We also cover their international subsidiaries around the world. And what is terrific about the middle market space, they're a real driver of the economy right now. They're driving growth, they're driving hiring, and they're driving innovation. And when we look at what that means for us at Bank of America, that's driving deposits, it's driving lending, and it's driving strategic activity. And most notably, M &A has been a big opportunity for our client base across the middle market space. And they're using M &A to grow, to manage supply chain, to bring costs down, and then also to expand globally.
26:33So what's driving the M &A? And we were talking private equity last week and somebody who's in middle market private equity. And a big narrative there is that there are a lot of family businesses that the people, you know, maybe they're second generation or first generation businesses and they don't have their heirs do not want to continue to run the business. Is that is that driving M &A? That's part of it. You know, we see when we talk about the. That was like the opportunity for private. So so for us, you know, when we look at the privately held companies that we cover, a lot of them now are run by third, fourth or fifth generation.
27:08So they have had succession planning that has worked well. You know, it's not to say that there are companies that don't have that opportunity. And so they do look to sell. But it's not that binary. You know, some of our clients that, you know, would like to have a liquidity event. They want to take, you know, some of the valuation off the table. And so they might sell a portion of the company, but not the whole thing. They continue to run the company. Some companies are looking at M &A. They want to acquire other companies because they're really looking to grow, whether that is grow geographically, whether it is sector adjacent.
27:42And then other companies are looking to solve for specific challenges that they're facing. Supply chain has been a real consideration. And so where they can diversify supply chain and look to grow globally, they've been doing that too. Would these firms say globalization is dead or not dead? Because it sounds like they're growing internationally if they're also thinking about supply chains around the world. To me, it would say no, but tell me what you're hearing. I would say it's evolving. So if you remember a few years ago, there was a lot of conversation about friend shoring, reshoring, near shoring, and a lot of our client base did that.
28:12However, the world continues to change. And given the geopolitical uncertainty, clients have to be flexible. And so an area that might have been a really good opportunity for them may not be as appealing. And conversely, an area they've gone into, they want to double down. The other thing that we're finding is that as clients are diversifying, they leave opportunity in one part of the world. and they're not looking to move that into a different part of the world. So they can then protect the business ecosystem in Europe, as an example. Go ahead, Carol. All I want to ask you is what's the relationship?
28:43Because you said you work in North America, so U.S. and Canadian firms. What's the relationship between U.S. and Canada based on your clients that are doing stuff back and forth? What's the reality? So the reality is that the relationships are strong. So I'll set politics aside. We don't focus as much on the politics. We focus on what the business relationships are like. those relationships. It can, but what I would say is that, look, our clients are much more pragmatic than they are political. And so, you know, they want to make sure that they are well positioned to continue to grow their companies.
29:13And the best way to do that is to have the right partners cross border. And there is a lot of back and forth between the U.S. and Canada. And, you know, the Canadian-based companies that we work with, the U.S. is an important market for them, as are other markets outside of North America. And so, regardless of where they're doing business, we're able to support them. The companies that you cover, it's very diverse. It's geographically diverse. It's diverse in terms of industries. But are there certain areas where you see strength versus weakness, not geographically, but in sectors? I would say we're seeing a lot of strength in most of the sectors that we cover.
29:50That's by design. We want to cover sectors that are growing so that we can continue to do business over the long period of time. They have different challenges, different opportunities. You know, if you're looking at manufacturing, there's a lot of growth in manufacturing, but talent can be a challenge. If you're looking at healthcare, there's a lot of growth in healthcare, but the capital investment required for healthcare, that's an opportunity, but it's also an expense. And every sector has different opportunities and challenges. You know, we talk so much about geopolitics and White House actions, but would Would you say that there are bigger themes and trends that are much more important to that middle market space?
30:29Yes. One is AI, which I am sure you are thinking about. But the way our clients are thinking about it might be a little bit different than what you would expect. I mean, our clients are thinking about how to use AI to do four things. The first is they've got to deliver a better customer experience. The second thing they're looking to do is enable frontline employees. The third thing is to improve process. And the fourth thing is to drive efficiency. And in order to do that, they've got to make sure that they have their data in order. They've got to make sure they understand their processes. And then look at how to overlay AI so that they can get the benefits that AI will deliver.
31:06And one or more of those four things that I've mentioned. How are you using AI? Well, we have a similar approach at Bank of America. And so we, too, also have looked at all of our data. We've got our data well organized so we can utilize it. I actually think it's the holy grail for us. I mean, when you think about the number of clients that we cover, not only in global commercial banking, but across our company, we have millions and millions of clients. And so we have a lot of data, but the data is only as good as the insights that we can pull from it. So we've been very focused on how to do that across all of our lines of business.
31:40Great stuff. Come back soon. Thank you. Enjoyed it. Wendy Stewart, president of global commercial banking over at Bank of America, joining us right here in studio. Stay with us. more from Bloomberg Business Week Daily coming up after this.
32:18spend, small cap stocks with improving operating margins, or the S &P 500 minus high debt companies. Chances are there isn't an ETF that fits your exact criteria. But on public, you just type in a prompt and their AI screens thousands of stocks and build a one-of-a-kind index. You can even backtest it against the S &P 500. Then you can invest in a few clicks. Go to public.com slash market and earn an uncapped 1 % bonus when you transfer your portfolio. That's public.com slash
33:08We believe in starting with your financial goals, not a formula. At Oppenheimer, we put the full strength of our longstanding expertise to work. understanding your life and your ambitions, and designing the precise strategies that build and protect your wealth with confidence across this generation and the next. Put the power of Oppenheimer thinking to work for you. Wealth management, capital markets, investment banking.
33:38Innovation is what gets your business to market. And Wasabi is designed to give every business a shot at competition. How? Break free from skyrocketing storage costs and unpredictable egress fees from old and top-heavy legacy providers. You know, the big guys. Wasabi is the world's hottest cloud storage company and the go-to provider for professional and collegiate sports teams and leagues around the world. And here's why. Innovation. From Wasabi's AI-enabled intelligent media storage, Wasabi Air, to the industry's only cloud storage service with triple protection against cybercriminals, data deletion and ransomware, the world's top companies trust Wasabi.
34:19Remember, Wasabi is up to 80 % less than market competition and doesn't charge a cent for businesses to access their own data. Wasabi, another championship story. Check them out for free at wasabi.com. Wasabi Hot Cloud Storage, proud partner of iHeart Podcast Network. You're listening to the Bloomberg Business Week Daily Podcast. Catch us live weekday afternoons from 2 to 5 p.m. Eastern. Listen on Apple CarPlay and Android Auto with the Bloomberg Business app. Or watch us live on YouTube. Back in April, Carol came into the office. She was raving about this New York Times article. It was about longevity.
34:59And it was about sort of identifying longevity at the cellular level and understanding not just the money that's going into it. We're obsessed with this, like the money going into it, the billionaires who are trying to live forever. But also what mainstream medicine can actually learn. from longevity. Well, they talked about cellular rejuvenation, you know, and how this could really change humanity. And it's apparently a new therapy. But anyway, it made it, it made us really, when anything comes up in terms of longevity, we wanted to hear more. Dr. Karina Kern and Serena Kern-Libera think about this stuff a lot.
35:34Dr. Karina Kern is founder and CEO of Longevity. Serena Kern-Libera is chief operating officer of the firm. They both join us from London. Good to have you both with us. Dr. Karina Kern, I want to start with you and have you explain how exactly longevity is intervening when it comes to the biological triggers of aging. What have you learned? What have we learned? Absolutely. I mean, I'll start with our name. So, longevity. It is linking medicine to longevity. And in effect, what we have is our flagship therapeutic. It is a first-in-class drug to take out negative cell death or necrosis, which underlies tissue degeneration.
36:15Our aim now is to take it into clinical trials. And, you know, we see this as such a valuable therapeutic target because necrosis as a process, I mean, there have been attempts to block it since the 1970s, which have failed. And the key here is if you look at where it is implicated across disease, it's not just one, but multiple different age-related diseases. And so vast potential. So Serena, come on in on this. So help me understand exactly how this works. And I feel like anything like this in terms of getting approval is going to take some time. So walk us through some of that. I think the beauty of what Karina just described is this is a paradigm shift.
36:59And as she said, This is really rethinking how medicine has looked at diseases and has looked at the downward spiral in health that you see as we age. We've taken a very much a systems biology approach. So the question is, how do you find a node within the system, within our biological system that can hit multiple diseases simultaneously? And that's what our drug potentially can do for the first time. That's what's really exciting here. You said potentially. So we know, we understand that this process can take years, certainly for development and then also to get approval. So where are you guys, Dr.
37:44Kern, where are we in this process? Absolutely. So how do you get good data without having to wait for the decade-long clinical trials while still maintaining the high bar of scientific rigor? And the answer is to use an accelerated aging model. So we've picked one indication to begin with. I like to call it a gateway clinical trial. It is kidney disease. It's one of the organs that really shows accelerated degeneration. And so it can give you that expedited data you use to springboard then onto other indications in the aging process as a whole. Serena, come on back in here. The evidence that you've seen, and Carol was asking how it worked, but the evidence that you've seen, what would you need to see from regulators to make this treatment mainstream and be approved by regulators, whether we're talking about UK, Europe, or the United States?
38:40it's a really good question i think you have to take a step back and you have to you have to look at the longevity sector as a whole um and there are lots of therapeutics out there that uh play in in the kind of unregulated space um we are very much in the hardcore regulated regulated sector this is a drug which will need to be approved and rightly so we're talking about human lives human health here. So I think very much as Karina said, we are working with regulators on this. We are following that regulatory process. We have selected an indication that you have to start with, but it is very much what we hope.
39:17This is subject to where we get to. It's obviously always subject to the data that you see, that it will be a gateway indication to multiple other diseases. So Serena, is this something that actually prevents aging or is it a case of when aging starts to occur that reverses it. Yeah, so I can go into the biology for you if that helps. And necrosis, as I said, is unwanted cell death that underlies tissue degeneration. And so I think the preventative side is pretty clear. If you can shield cells from stress, from cellular damage and stop this unwanted cell death, you have that preventative side.
39:55But the other side of necrosis, and this is where the potential for regenerative capacity comes in, is negative cell death is where the cell spews out hazardous contents into the surrounding tissue. And typically that then kickstarts these destructive, vicious, self-reinforcing feedback loops of damage. So it triggers what's known as zombie cells and unwanted inflammatory profile within the tissue fibrosis. And the point is we haven't been able to hit those positive feedback loops at their heart. And the potential here is if you can do that, you would be in a situation where you could allow normal cell division to come back and normal physiology to come back and therefore regeneration.
40:39So, yeah, and that's what I think that Times article, right, got into this whole idea of cellular rejuvenation or regeneration. So, and I'm not quite sure who should answer this. Um, so how long before this is something that if it really does work, as you say, that people could be using it? And Serena or Karina, Karina, you want to come in on that? Yeah, I mean, look, we are going down the highest level of scientific and regulatory rigor. So all of this is going to be subject to regulatory approval. But of course, we've chosen selectively chosen an indication where hopefully you're looking at a few years rather than the decade long clinical trials.
41:25okay can i'm just curious about like your view of of the mainstream medical industry in the united states right now and and there's been a lot of criticism of the way that doctors think about health holistically and there's this been this big movement for functional medicine in the united states and you know that's not necessarily viewed there's a lot of tension within the medical industry right now about what doctors are some doctors are doing you know selling stuff that you know insurance doesn't cover and that can cost thousands of dollars that only really wealthy people can afford and at the end of the day it's like a total waste of money Dr.
42:07Kern where does this come in in terms of mainstream medicine yeah again we are very much focused in the mainstream medicine side and at the end of the day, you want a therapeutic that is widely accessible and widely available. I think the key is if you take a step back, medicine, drug discovery, we need a paradigm shift. I mean, look at how medicine evolved. It evolved to tackle diseases you get early in life, where typically you have a single underlying cause, like an infectious agent, versus look at aging. What do you see? You see multi-morbidity, multiple diseases arising simultaneously. continuously they're interlinked you see that they are multifactorial multiple factors can give rise into the same disease and so the point is you need a paradigm shift where you're no longer just developing a single drug for a single target for a single disease how do you know how do you know if if a disease that a person has again i don't know if this is better for korena or serena how do you know if a if a disease that a person has is related to aging versus to something that's completely separate?
43:18Oh, that's a great question. And this is why causal mechanisms are so important. You need very well characterized mechanisms that demonstrate how age-related change is linked to a tangible outcome, which is the disease, right? And I think the way you need to think about it is aging, the process, the mechanisms, they're interlinked to the tangible diseases and the tangible pathologies you see later in life. And the point is, you need to be working on processes where you know, you know, from A to B to C, what the causal chain is and then where to intervene within that chain. And for me, necrosis is such a powerful therapeutic target because those mechanisms have been characterized for the last decades.
44:03So I am curious about, we are Bloomberg, and just curious about who is funding you? How are you guys doing this research? Who are you doing this research with? Yeah. So, to date, our approach has been to be as frugal as possible and to get to the, from a commercial perspective, speaking from a commercial perspective, to get to the highest value inflection point that we can so that we're then ready to go out there to institutions and raise for the clinical trial. So, that's where we are at the moment. We've been funded by family offices, by grants as well. So we've been backed by UK government grants, by EU grants.
44:48The UK Space Agency as well, and NASA Space H program sponsored us as well. So that's the approach so far. We are gearing up for our clinical trial, which will require institutional backing. But that's kind of the staggered approach that we've taken, which we think makes commercial sense. And again, remind us when that clinical trial gets underway. And I'm not sure if Karina or Serena should take that. Yeah. So again, it's going to be subject to regulatory approval, but this is very much the next step for us. So once we finish our fundraising round, it would be just following that. As you know, a lot of biotech companies that don't necessarily even have a drug to market end up going public.
45:34Serena, is that something that you would do? that don't, uh, drug companies that don't have a drug to market, did you say? Yeah. Are still publicly traded companies. I think, you know what, I think we've seen a lot of companies who go out there, they raise a lot of money early on. Um, and you know, 10 years down the line, don't have a single drug product. And I'd like to say that's what, you know, distinguishes us in many ways. Um, our process managed to discover a drug within 12 months, that we're ready to take into clinical trials. And if you look at the preclinical data, I mean, the data always speaks for itself.
46:13So I think that that is one thing that would distinguish us is what I'd say. Well, certainly taking the most frugal approach to the highest value inflection point. I totally get that. We'll stay in touch. Let us know how things are going. Dr. Karina Kern and Serena Kern-Libera. Dr. Kern is the founder and CEO of Lingevity and Serena is the Chief Operating Officer. This is Bloomberg. This is the Bloomberg Business Week Daily Podcast. Available on Apple, Spotify, and anywhere else you get your podcasts. Listen live weekday afternoons from 2 to 5 p.m. Eastern on Bloomberg.com, the iHeartRadio app, TuneIn, and the Bloomberg Business app.
46:55You can also watch us live every weekday on YouTube and always on the Bloomberg Terminal.
47:09So as a pizza genius, I know pizza shop orders come from, well, everywhere. With Genius by Global Payments, online orders actually sink straight into your kitchen. It's as simple as pie. And with digital menu boards, your specials, your prices, your brand, always front and center. It's one system, ready for game night crowds. Any night of the week, really. Cheers. Big League reliability for any business. That's genius. Here's the truth. You could literally be adored by everyone and then come home and still get completely ignored by your own cat. It's classic cat behavior. But new Shiba Premium Puree is a lickable treat that changes all that.
47:51They're protein-rich, made with bone broth, and have the smooth, creamy texture cats go crazy for. Especially when it's hand-fed. Yeah, it's more than a treat. It's a fast pass to favorite human status. So feed your cat Sheba and go from totally ignored to truly adored in just 12 days, guaranteed, or your money back. Learn more at Sheba.com. If your best finance people are doing expense reports, chasing receipts, or spending time on month-end close, it's time to get Brex AF, a gentic finance that eliminates that work before it starts. Learn more at Brex.com slash AF.
From the publisher
The people, companies and trends shaping the global economy. Watch Carol and Tim LIVE every day on YouTube: http://bit.ly/3vTiACF.
Famed short seller Andrew Left faces the possibility of decades behind bars after being found guilty of using disingenuous social media posts to manipulate stocks, in a landmark case that threatens to chill a broader trading strategy loathed by corporate executives.
Left, who gained a large online following with his blunt commentary about major US companies as well as smaller stocks popular with retail traders, was convicted Monday following a three-week trial in Los Angeles. Even before his conviction, his 2024 indictment spooked the industry and led some short sellers to beef up legal disclaimers.
Now, the 55-year-old faces more than two decades behind bars at an Aug. 31 sentencing hearing, though criminal defendants frequently get less time. Left will remain free until then.
On this episode, Carol Massar and Tim Stenovec speak with:
- Erik Larson, Bloomberg News US Legal Reporter
- Ed Zitron, CEO at EZ Primary Research on AI skepticism
- Wendy Stewart, President of Global Commercial Banking at Bank of America on trends currently shaping the business landscape
- Dr. Carina Kern, Founder and CEO of LinkGevity & Serena Kern-Libera, Chief Operating Officer at LinkGevity on Reshaping Aging, Longevity
See omnystudio.com/listener for privacy information.
